141 related articles for article (PubMed ID: 28923620)
1. Late Conversion to Belatacept After Kidney Transplantation: Outcome and Prognostic Factors.
Dürr M; Lachmann N; Zukunft B; Schmidt D; Budde K; Brakemeier S
Transplant Proc; 2017 Oct; 49(8):1747-1756.e1. PubMed ID: 28923620
[TBL] [Abstract][Full Text] [Related]
2. Conversion From Calcineurin Inhibitors to Belatacept in HLA-sensitized Kidney Transplant Recipients With Low-level Donor-specific Antibodies.
Ulloa CE; Anglicheau D; Snanoudj R; Scemla A; Martinez F; Timsit MO; Legendre C; Sberro-Soussan R
Transplantation; 2019 Oct; 103(10):2150-2156. PubMed ID: 30720681
[TBL] [Abstract][Full Text] [Related]
3. Experience with belatacept rescue therapy in kidney transplant recipients.
Brakemeier S; Kannenkeril D; Dürr M; Braun T; Bachmann F; Schmidt D; Wiesener M; Budde K
Transpl Int; 2016 Nov; 29(11):1184-1195. PubMed ID: 27514317
[TBL] [Abstract][Full Text] [Related]
4. Microvascular inflammation is a risk factor in kidney transplant recipients with very late conversion from calcineurin inhibitor-based regimens to belatacept.
Choi M; Bachmann F; Wu K; Lachmann N; Schmidt D; Brakemeier S; Duerr M; Kahl A; Eckardt KU; Budde K; Nickel P
BMC Nephrol; 2020 Aug; 21(1):354. PubMed ID: 32819287
[TBL] [Abstract][Full Text] [Related]
5. Late conversion from tacrolimus to a belatacept-based immuno-suppression regime in kidney transplant recipients improves renal function, acid-base derangement and mineral-bone metabolism.
Schulte K; Vollmer C; Klasen V; Bräsen JH; Püchel J; Borzikowsky C; Kunzendorf U; Feldkamp T
J Nephrol; 2017 Aug; 30(4):607-615. PubMed ID: 28540602
[TBL] [Abstract][Full Text] [Related]
6. Conversion to Belatacept in Maintenance Kidney Transplant Patients: A Retrospective Multicenter European Study.
Darres A; Ulloa C; Brakemeier S; Garrouste C; Bestard O; Del Bello A; Sberro Soussan R; Dürr M; Budde K; Legendre C; Kamar N
Transplantation; 2018 Sep; 102(9):1545-1552. PubMed ID: 29570163
[TBL] [Abstract][Full Text] [Related]
7. Early conversion to belatacept after renal transplantation.
Nair V; Liriano-Ward L; Kent R; Huprikar S; Rana M; Florman SS; Delaney VB; Menon MC; Sehgal V; Miko L; Khaim R; Benvenisty A; Lerner S; Arvelakis A; Wadhera V; Ames S; Shapiro R
Clin Transplant; 2017 May; 31(5):. PubMed ID: 28267882
[TBL] [Abstract][Full Text] [Related]
8. Early post-transplant conversion from tacrolimus to belatacept for prolonged delayed graft function improves renal function in kidney transplant recipients.
Wojciechowski D; Chandran S; Vincenti F
Clin Transplant; 2017 May; 31(5):. PubMed ID: 28190259
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of Conversion From Calcineurin Inhibitor to Belatacept-based Immunosuppression in HLA-sensitized Kidney Transplant Recipients.
Sethi S; Najjar R; Peng A; Choi J; Lim K; Vo A; Jordan SC; Huang E
Transplantation; 2020 Jul; 104(7):1500-1507. PubMed ID: 31568398
[TBL] [Abstract][Full Text] [Related]
10. Early Conversion to Belatacept in Kidney Transplant Recipients With Low Glomerular Filtration Rate.
Abdelwahab Elhamahmi D; Heilman RL; Smith B; Huskey J; Khamash H; Kaplan B
Transplantation; 2018 Mar; 102(3):478-483. PubMed ID: 29077658
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Outcomes after Conversion to a Belatacept-Based Immunosuppression in Kidney Transplant Recipients.
Divard G; Aubert O; Debiais-Deschamp C; Raynaud M; Goutaudier V; Sablik M; Sayeg C; Legendre C; Obert J; Anglicheau D; Lefaucheur C; Loupy A
Clin J Am Soc Nephrol; 2024 May; 19(5):628-637. PubMed ID: 38265815
[TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial.
Grinyó JM; Del Carmen Rial M; Alberu J; Steinberg SM; Manfro RC; Nainan G; Vincenti F; Jones-Burton C; Kamar N
Am J Kidney Dis; 2017 May; 69(5):587-594. PubMed ID: 27889299
[TBL] [Abstract][Full Text] [Related]
13. Conversion to belatacept within 1-year of renal transplantation in a diverse cohort including patients with donor-specific antibodies.
Santeusanio AD; Bhansali A; Weinberg A; Shapiro R; Delaney V; Florman S; De Boccardo G
Clin Transplant; 2020 Apr; 34(4):e13823. PubMed ID: 32049378
[TBL] [Abstract][Full Text] [Related]
14. Safe Conversion From Tacrolimus to Belatacept in High Immunologic Risk Kidney Transplant Recipients With Allograft Dysfunction.
Gupta G; Regmi A; Kumar D; Posner S; Posner MP; Sharma A; Cotterell A; Bhati CS; Kimball P; Massey HD; King AL
Am J Transplant; 2015 Oct; 15(10):2726-31. PubMed ID: 25988397
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcome of belatacept therapy in de novo kidney transplant recipients - a case-match analysis.
Schwarz C; Mayerhoffer S; Berlakovich GA; Steininger R; Soliman T; Watschinger B; Böhmig GA; Eskandary F; König F; Mühlbacher F; Wekerle T
Transpl Int; 2015 Jul; 28(7):820-7. PubMed ID: 25703346
[TBL] [Abstract][Full Text] [Related]
16. Does belatacept improve outcomes for kidney transplant recipients? A systematic review.
Talawila N; Pengel LH
Transpl Int; 2015 Nov; 28(11):1251-64. PubMed ID: 25965549
[TBL] [Abstract][Full Text] [Related]
17. Prevention of acute rejection after rescue with Belatacept by association of low-dose Tacrolimus maintenance in medically complex kidney transplant recipients with early or late graft dysfunction.
Gallo E; Abbasciano I; Mingozzi S; Lavacca A; Presta R; Bruno S; Deambrosis I; Barreca A; Romagnoli R; Mella A; Fop F; Biancone L
PLoS One; 2020; 15(10):e0240335. PubMed ID: 33057374
[TBL] [Abstract][Full Text] [Related]
18. Minimum mycophenolic acid levels are associated with donor-specific antibody formation.
Filler G; Todorova EK; Bax K; Alvarez-Elías AC; Huang SH; Kobrzynski MC
Pediatr Transplant; 2016 Feb; 20(1):34-8. PubMed ID: 26589470
[TBL] [Abstract][Full Text] [Related]
19. Belatacept Rescue Therapy in Kidney Transplant Recipients With Vascular Lesions: A Case Control Study.
Bertrand D; Cheddani L; Etienne I; François A; Hanoy M; Laurent C; Lebourg L; Le Roy F; Lelandais L; Loron MC; Godin M; Guerrot D
Am J Transplant; 2017 Nov; 17(11):2937-2944. PubMed ID: 28707779
[TBL] [Abstract][Full Text] [Related]
20. Switching renal transplant recipients to belatacept therapy: results of a real-life gradual conversion protocol.
Malvezzi P; Fischman C; Rigault G; Jacob MC; Raskovalova T; Jouve T; Janbon B; Rostaing L; Cravedi P
Transpl Immunol; 2019 Oct; 56():101207. PubMed ID: 31071442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
